Drug Trial Radar · NCT07553429
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
49
Planned (sponsor's estimate)
Start
May 14, 2026
Primary completion
Mar 23, 2027
Study completion Jul 6, 2027
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Apr 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with diabetic macular edema that involves the center of the eye. The purpose of this study is to find out how well different doses of a medicine called BI 3812465 are tolerated by people with this condition. This is the first time BI 3812465 is given to humans. This study has 2 parts. In Part 1, a small number of participants receive low, medium, or high doses of BI 3812465. The first participants to start the study get low doses of BI 3812465. Participants who start later get higher doses only if the lower doses were tolerated. In Part 2, a larger number of participants are placed into low, medium, or high dose groups. Participants in both parts of the study get BI 3812465 as injections into the back of the eye for a total of 3 eye injections. Participants are in the study for up to 7 months. During this time, they visit the study site 19 times. Where possible, some visits can be done at the participant's home instead of the study site. At study visits, the doctors check the severity of participants' eye condition and note any health problems that could have been caused by BI 3812465.
Conditions
- Diabetic Macular Edema
Interventions
Low dose BI 3812465Biological
BI 3812465
Medium dose BI 3812465Biological
BI 3812465
High dose BI 3812465Biological
BI 3812465
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Occurrence of dose limiting events (DLEs) from first investigational medicine product (IMP) administration until end of study (EOS)Time frame: Up to 169 days.
- Part 2: Occurrence of ocular adverse events (AEs) in the study eye from first IMP administration until EOSTime frame: Up to 169 days.
Locations
29 sites in 2 countries. Site status is shown where the registry gives one.
Associated Retina Consultants, Ltd.
Phoenix, Arizona · Recruiting
Research Network Arizona
Scottsdale, Arizona · Recruiting
Win Retina
Arcadia, California · Recruiting
Retina-Vitreous Associates Medical Group
Beverly Hills, California · Recruiting
Global Research Management
Glendale, California · Recruiting
Retina Associates of Southern California
Huntington Beach, California · Recruiting
California Retina Consultants-Oxnard-70187
Oxnard, California · Recruiting
Retinal Consultants Medical Group
Sacramento, California · Recruiting
Bay Area Retina Associates - Walnut Creek
Walnut Creek, California · Recruiting
Retina Group of New England, PC
Waterford, Connecticut · Recruiting
Retina Group of Florida - Fort Myers Retina Center
Fort Myers, Florida · Recruiting
Florida Retina Consultants
Lakeland, Florida · Recruiting
East Florida Eye Institute
Stuart, Florida · Recruiting
Ophthalmic Consultants of Long Island
Oceanside, New York · Recruiting
North Carolina Retina Associates
Wake Forest, North Carolina · Recruiting
Red River Research Partners, LLC
Fargo, North Dakota · Recruiting
Cleveland Clinic
Cleveland, Ohio · Not yet recruiting
Verum Research, LLC
Eugene, Oregon · Recruiting
EyeHealth Northwest
Portland, Oregon · Recruiting
Tennessee Retina
Nashville, Tennessee · Recruiting
Austin Clinical Research, LLC
Austin, Texas · Recruiting
Retina Consultants of Texas-Bellaire-67493
Bellaire, Texas · Recruiting
Valley Retina Institute, PA
McAllen, Texas · Recruiting
Medical Center Ophthalmology Associates
San Antonio, Texas · Recruiting
Retina Consultants of Texas
San Antonio, Texas · Recruiting
Retina Consultants of Texas-The Woodlands-67575
The Woodlands, Texas · Recruiting
Strategic Clinical Research Group
Willow Park, Texas · Recruiting
Emerson Clinical Research Institute
Falls Church, Virginia · Recruiting
Emanuelli Research & Development Center
Arecibo, Puerto Rico · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.